China's first personalized tumor newborn antigen vaccine has been approved by NMPA to enter the clinical stage
On March 15, 2023, the website of the Center for Drug Review and Evaluation (CDE) of the State Medical Products Administration updated the data in the column of clinical trial implied approval. Beijing Likang Life Science and Technology Co., LTD. 's personalized tumor neonatal antigen vaccine product -- LK101 injection was approved for clinical trial implied approval, indicating advanced solid tumors.
LK101 injection is the first core pipeline completely independently developed by Licon. It is a personalized tumor neonatal antigen vaccine, which adopts the form of MRNA-DC vaccine. By transferring the mRNA encoding dozens of personalized tumor antigen targets designed based on the patient's autologous tumor mutation information into dendritic cells, Thus, both mRNA vaccine and DC vaccine have advantages.